171 related articles for article (PubMed ID: 36579085)
21. Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Nagral A; Jhaveri A; Sawant S; Parikh NS; Nagral N; Merchant R; Gandhi M
Indian J Pediatr; 2019 Feb; 86(2):148-153. PubMed ID: 30097845
[TBL] [Abstract][Full Text] [Related]
22. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
Dhiman RK; Grover GS; Premkumar M; Taneja S; Duseja A; Arora S; Rathi S; Satsangi S; Roy A;
J Hepatol; 2019 Dec; 71(6):1076-1085. PubMed ID: 31325468
[TBL] [Abstract][Full Text] [Related]
23. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals.
Huang Y; Li MH; Hou M; Xie Y
Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):470-479. PubMed ID: 28992878
[TBL] [Abstract][Full Text] [Related]
24. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
25. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
[TBL] [Abstract][Full Text] [Related]
26. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
27. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.
Zarębska-Michaluk D; Brzdęk M; Jaroszewicz J; Tudrujek-Zdunek M; Lorenc B; Klapaczyński J; Mazur W; Kazek A; Sitko M; Berak H; Janocha-Litwin J; Dybowska D; Supronowicz Ł; Krygier R; Citko J; Piekarska A; Flisiak R
World J Gastroenterol; 2022 Dec; 28(45):6380-6396. PubMed ID: 36533109
[TBL] [Abstract][Full Text] [Related]
28. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
Polepally AR; Badri PS; Eckert D; Mensing S; Menon RM
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):333-339. PubMed ID: 27165046
[TBL] [Abstract][Full Text] [Related]
29. Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.
Aluzaite K; Fraser M; Johnson S; Giles H; Schultz M
N Z Med J; 2020 Nov; 133(1525):53-61. PubMed ID: 33223548
[TBL] [Abstract][Full Text] [Related]
30. Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation.
Wu SH; Loong CC; Chu CJ; Su CW; Lin CC; Hsia CY; Liu C; Lee SD; Wang YJ; Lee FY; Linb NC; Chen CY; Huang YH; Hou MC
J Chin Med Assoc; 2020 Jan; 83(1):18-24. PubMed ID: 31714442
[TBL] [Abstract][Full Text] [Related]
31. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Feld JJ; Moreno C; Trinh R; Tam E; Bourgeois S; Horsmans Y; Elkhashab M; Bernstein DE; Younes Z; Reindollar RW; Larsen L; Fu B; Howieson K; Polepally AR; Pangerl A; Shulman NS; Poordad F
J Hepatol; 2016 Feb; 64(2):301-307. PubMed ID: 26476290
[TBL] [Abstract][Full Text] [Related]
32. Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?
Premkumar M; Grover GS; Dhiman RK
J Clin Exp Hepatol; 2017 Sep; 7(3):253-261. PubMed ID: 28970713
[TBL] [Abstract][Full Text] [Related]
33. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data.
Hong CM; Liu CH; Su TH; Yang HC; Chen PJ; Chen YW; Kao JH; Liu CJ
J Microbiol Immunol Infect; 2020 Aug; 53(4):569-577. PubMed ID: 30316726
[TBL] [Abstract][Full Text] [Related]
34. Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4.
Abad S; Vega A; Hernández E; Mérida E; de Sequera P; Albalate M; Macías N; Milla M; López-Gómez JM
Am J Nephrol; 2017; 45(3):267-272. PubMed ID: 28166520
[TBL] [Abstract][Full Text] [Related]
35. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Asselah T; Hézode C; Qaqish RB; ElKhashab M; Hassanein T; Papatheodoridis G; Feld JJ; Moreno C; Zeuzem S; Ferenci P; Yu Y; Redman R; Pilot-Matias T; Mobashery N
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):25-35. PubMed ID: 28404108
[TBL] [Abstract][Full Text] [Related]
36. Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience.
Bwa AH; Nangia G; Win STS; Maung ST; Han KAW; Htar SS; Wine LY; Ko WW; Oo MP; Hlaing NKT; Palecki J; Loza BL; Win KM; Reddy R
J Clin Exp Hepatol; 2019; 9(3):283-293. PubMed ID: 31360020
[TBL] [Abstract][Full Text] [Related]
37. Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review.
Mantry PS; Pathak L
Expert Rev Anti Infect Ther; 2016; 14(2):157-65. PubMed ID: 26567871
[TBL] [Abstract][Full Text] [Related]
38. Distribution of chronic hepatitis C genotype and evaluation of clinical factors affecting direct-acting antiviral treatment responses in the Western Black Sea Region, Turkey.
Gok Sargin Z; Dusunceli I
Eur Rev Med Pharmacol Sci; 2022 Oct; 26(19):7256-7262. PubMed ID: 36263536
[TBL] [Abstract][Full Text] [Related]
39. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
